Given the destabilization effects of cyclin D-CDK4 kinase on PD-L1 protein [152], therapeutic application of the PD-L1/PD-1 blockade has been verified in the CDK4/6 inhibitor-induced senescence scenarios in various malignancies including colorectal cancer [152], melanoma [153,154] and lung cancer [155]. The gene discussed is CD274; the disease is colorectal cancer.